Compare GSK plc (GSK) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PepsiCo, Inc. — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while PepsiCo, Inc. trades at $126.04 (market cap $174.89B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and PepsiCo, Inc. for 107 Days on average.
| GSK | PEP | |
|---|---|---|
Market Cap | $91.88B | $174.89B |
Volume | 7,730,529 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $170.44 |
52-Week Low | $43.24 | $123.64 |
Typical Hold Time | 93 Days | 107 Days |
Enterprise Value | $111.88B | $215.61B |
Dividend Yield | 3.9% | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
PepsiCo (PEP) trades at $125.97, up 1.88% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding the $2.29 estimate. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Analysts maintain a consensus price target of $146.77, implying significant upside. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while institutional holdings saw mixed adjustments.
The outlook for PEP is cautiously optimistic, driven by earnings momentum and a reasonable P/E of 16.14. Risks include competitive pressures and sensitivity to consumer spending. The stock offers a dividend yield near 4%, supporting income-focused investors. Upside potential exists if North American performance improves, but volatility may persist amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
